Rimini Street Inc. Partners with Apsen Farmacêutica for Enterprise Workflow Automation Initiative

Reuters
08 May
Rimini Street Inc. Partners with Apsen Farmacêutica for Enterprise Workflow Automation Initiative

Rimini Street Inc., a global provider of enterprise software support and innovation solutions, has announced a partnership with Apsen Farmacêutica, a Brazilian pharmaceutical manufacturer. The collaboration, which involves ServiceNow, aims to implement a next-generation vision of enterprise-wide workflow automation. By layering ServiceNow over its existing SAP ECC 6 ERP platform, Apsen Farmacêutica seeks to enable intelligent workflow and automation, enhancing business responsiveness, reducing information silos, and improving operational efficiency. This strategic move allows Apsen to avoid costly and risky vendor-mandated migration to SAP S/4HANA, ensuring immediate business impact.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rimini Street Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250507517040) on May 07, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10